NCT06228573 Transcranial Direct Current Stimulation and Yoga for Knee Osteoarthritis
| NCT ID | NCT06228573 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McMaster University |
| Condition | Knee Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2024-10-20 |
| Primary Completion | 2025-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2024-10-20 with a primary completion date of 2025-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People with knee arthritis often experience constant pain, and current treatments aren't very effective. This can lead to limited movement and more health problems. Knee arthritis is a big part of healthcare costs in Canada, and its pain is a major reason people see doctors. The pain is linked to complex nervous system changes, making current treatments, like exercise, not very successful. To address this, researchers suggest a new approach combining two things: a brain stimulation technique called Transcranial Direct Current Stimulation (tDCS) and yoga. TDCS helps with pain by changing how the brain works, and yoga, a safe practice, focuses on overall well-being. Together, the investigators aim to improve how the nervous system works from top to bottom. The research project wants to change how the arthritis pain is being managed by focusing on how it works. The investigators plan to test this combo in a study comparing real tDCS plus yoga with fake tDCS plus yoga. The investigators will look not only at pain but also at other measures related to pain and how the nervous system works. This new mix could be a meaningful way to reduce pain for people with knee arthritis.
Eligibility Criteria
Inclusion Criteria: * community dwelling adults from Sherbrooke, Quebec, Hamilton and London, Ontario fulfilling the NICE criteria for KOA * ≥45 years of age * Diagnosis of Knee osteoarthritis OR * Having movement-related joint pain with either no morning knee stiffness or stiffness of 30 minutes or less AND * Experiencing an average pain intensity of ≥3 /10 in the past month Exclusion Criteria: * Systemic inflammatory arthritis. * Any knee injection in the past 3 months. * Inability to independently get up and down from the floor. * Lower limb trauma or surgery within the last 6 months. * Current participation in another OA clinical trial. * Use of mobility aids. * Currently receiving care for KOA pain (e.g., physiotherapy). * Planned absences exceeding 1 week. * Contraindications to transcranial direct current stimulation (tDCS) such as neurological or neuropsychiatric conditions. * History of brain surgery or tumor. * Metallic implants. * Epilepsy or history of substance abuse or dependence. * Cochlear or ocular implant. * Presence of a pacemaker or cardiac defibrillator. * Eczema on the scalp.
Contact & Investigator
Lisa Carlesso, PhD
PRINCIPAL INVESTIGATOR
McMaster University
Frequently Asked Questions
Who can join the NCT06228573 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06228573 currently recruiting?
Yes, NCT06228573 is actively recruiting participants. Contact the research team at carlesl@mcmaster.ca for enrollment information.
Where is the NCT06228573 trial being conducted?
This trial is being conducted at Hamilton, Canada, London, Canada, Sherbrooke, Canada.
Who is sponsoring the NCT06228573 clinical trial?
NCT06228573 is sponsored by McMaster University. The principal investigator is Lisa Carlesso, PhD at McMaster University. The trial plans to enroll 68 participants.